$2.01
-0.07 (-3.37%)
Open$2.10
Previous Close$2.08
Day High$2.14
Day Low$1.98
52W High$3.40
52W Low$1.09
Volume—
Avg Volume942.4K
Market Cap208.17M
P/E Ratio—
EPS$-1.19
SectorBiotechnology
Analyst Ratings
Buy
14 analysts
Price Target
+959.7% upside
Current
$2.01
$2.01
Target
$21.30
$21.30
$14.71
$21.30 avg
$34.17
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 24.30M | 45.00M | 87.33M |
| Net Income | -165,074,630 | -275,073,443 | 8.20M |
| Profit Margin | -679.2% | -645.2% | 9.4% |
| EBITDA | -173,568,057 | -305,294,675 | 10.19M |
| Free Cash Flow | — | — | 6.96M |
| Rev Growth | -46.0% | -46.0% | +6.5% |
| Debt/Equity | 0.32 | 0.32 | 0.50 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $251.64 | -1.05% | 118.2 | 429.58B |
| AMGN | Amgen Inc | $362.12 | +0.44% | 24.8 | 193.10B |
| GILD | Gilead Sciences Inc | $126.34 | +0.01% | 17.1 | 157.21B |
| VRTX | Vertex Pharmaceuticals Inc | $496.73 | -0.58% | 28.1 | 121.87B |
| REGN | Regeneron Pharmaceuticals | $623.54 | -1.31% | 15.0 | 66.35B |
| ALNY | Alnylam Pharmaceuticals Inc | $301.03 | +2.56% | 69.3 | 39.97B |